Prognostic Factors for Disease-Free Survival in pT2N0 Non-Small Cell Lung Cancer

• Published in: Asian cardiovascular & thoracic annals 2006-04, Vol.14 (2), p.139-144
• Main Authors: Park, Inkyu, Chung, Kyung Young, Kim, Kil Dong, Kim, Dae Joon
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - therapy; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Female; Humans; Lung Neoplasms - diagnosis; Lung Neoplasms - mortality; Lung Neoplasms - therapy; Male; Middle Aged; Pneumonectomy; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Uracil
• ISSN: 0218-4923; 1816-5370
• DOI: 10.1177/021849230601400212

To clarify the prognostic factors for disease-free survival in completely resected pT2N0 non-small cell lung cancer, 81 consecutive patients who were treated between 1998 and 2001 were retrospectively reviewed. Follow-up was complete for all patients and the median follow-up time was 37.5 months. The overall 5-year survival rate was 68.6%, and the 5-year disease-free survival rate was 62.5%. Four factors (age, sex, visceral pleural invasion, and administration of tegafur and uracil) were proposed as prognostic factors for disease-free survival by univariate analysis. In multivariate analysis, visceral pleural invasion by the tumor (hazard ratio = 2.709, 95% confidence interval: 1.085 to 6.765, p = 0.033) and administration of tegafur and uracil (hazard ratio = 0.327, 95% confidence interval: 0.147 to 0.730, p = 0.006) were significant factors. Visceral pleural invasion was a prognostic factor for reduced disease-free survival in completely resected pT2N0 non-small cell lung cancer, and postoperative treatment with tegafur and uracil significantly improved disease-free survival.